Global Cell Based Assays Market

The stem cell/cord blood banking global market consists of sales of stem cell/cord blood banking services and related goods. Cord stem cells are referred to as regenerative medicines which help in regeneration of tissues or cells in the body. Stem cells therapy is designed to aid the physician in performing medical treatment of different types of cancers, neurodegenerative diseases, graft-versus-host disease and heart diseases. The stem cell/cord blood banking market covered in this report is segmented by cell type into adult stem cells, umbilical cord blood stem cells, embryonic stem cells. The stem cell/cord blood banking global market is also segmented by service into collection, processing, analysis, storage; by bank type into public, private; by application into leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, others. The global stem cell/cord blood banking market is expected to grow from $8.16 billion in 2020 to $8.61 billion in 2021 at a compound annual growth rate (CAGR) of 5.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The stem cell/cord blood banking global market is expected to reach $12.51 billion in 2025 at a CAGR of 9.8%. Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor. By using stem cells in the treatment of cancer, the blood forming stem cells which are damaged during chemotherapy can be restored. According to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer which can be treated by transplanting the stem cells. Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks. Hence, this option is not fully explored despite the advantages of stem cell transplantation in treating cancer. For example, according to the survey by International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy, just 5% were aware about the cost of the procedure and less than 1% were aware about the availability of cord blood banking. Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. The US Food and Drug Administration (FDA) outlines guidance related to stem cells/cord blood banking in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). As per this act, stem cells sourced from cord blood for unrelated allogeneic use are regulated by the FDA, and, in order to distribute these products, distributors need to get a license from the FDA. These licenses are provided by the FDA after reviewing the manufacturing and the storage conditions. In this regard, the American Association of Blood Banks (AABB) and other regulatory agencies also work with the FDA. Hence, the regulatory scenario related to the stem cells/cord blood banking market is expected to keep a check on companies involved in this market. In September 2019, CBR, a California Cryobank Life Sciences company acquired Natera's Evercord cord blood and tissue banking business for an undisclosed amount. This acquisition will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology and organ transplantation. Natera Inc, a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California. Major players in the stem cell/cord blood banking global market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, and Americord Registry LLC. The regions covered in the stem cell/cord blood banking global market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stem cell/cord blood banking global market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global stem cell/cord blood banking market is segmented - 1) By Cell Type: Adult Stem Cells, Umbilical Cord Blood Stem Cells, Embryonic Stem Cells 2) By Service: Collection, Processing, Analysis, Storage 3) By Bank Type: Public, Private 4) By Application: Leukemia, Anemia, Thalassemia, Autism, Cerebral Palsy, Diabetes, Others

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes and neurons. The induced pluripotent stem cell (iPSC) market covered in this report is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, others. The induced pluripotent stem cell (iPSC) market is also segmented by application into academic research, drug development and discovery, toxicity screening, regenerative medicine and by end-user into hospitals, research laboratories. The global induced pluripotent stem cell (iPSC) market is expected to grow from $2.22 billion in 2020 to $2.43 billion in 2021 at a compound annual growth rate (CAGR) of 9.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The induced pluripotent stem cell (iPSC) market is expected to reach $3.36 billion in 2025 at a CAGR of 8.4%. Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 Million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment. The potential risk of tumour is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the induced pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in November 2019, Notch Therapeutics and Allogene Therapeutics announced a partnership and licencing contract to research and develop induced pluripotent stem cell (iPSC) AlloCAR treatment goods for early use of leukaemia, multiple myeloma and non-Hodgkin lymphoma. Another Example is in January 2019, the New York Stem Cell Foundation (NYSCF) Research Institute made a strategic partnership with Ngene Therapeutics Inc. (Ngene) for the treatment of new diseases that will hold the human stem cell research and techniques like novel gene editing which means replacement of DNA at a specific cell. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2019, Bayer, a Germany based pharmaceutical and life sciences company acquired BlueRock Therapeutics LP for $600 million. Through the deal, Bayer would own full rights to BlueRock’s CELL+GENE™ platform, which is designed to create stable master cell banks capable of virtually unlimited expansion and differentiation into any cell type in the body, using proprietary bioprocessing and manufacturing techniques. BlueRock Therapeutics LP, an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc. and Fate Therapeutics. The regions covered in the induced pluripotent stem cell market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global iPSC market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others 2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories

The cell based assays market consists of sales of cell based assays. Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function. Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others. The cell based assays market covered in this report is segmented by product & service into consumables, instruments, services, software. The cell based assays market is also segmented by application into drug discovery, basic research, ADME studies, predictive toxicology, others; by end user into pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CRO), other end users; by technology into automated handling, flow cytometry, label-free detection, high-throughput screening, others; by consumables into reagents and media, cells and cell lines, probes and labels; by instruments into microplates, microplate readers, high throughput screening, liquid handling systems. The global cell based assays market is expected to grow from $17.49 billion in 2020 to $19.29 billion in 2021 at a compound annual growth rate (CAGR) of 10.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell based assays market is expected to reach $26.69 billion in 2025 at a CAGR of 8.5%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (high content analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In April 2019, PerkinElmer, a global corporation for diagnostics, life science research, food, environmental and industrial testing acquired Cisbio Bioassays for an undisclosed amount. The acquisition expands PerkinElmer's R&D capability in cell based assay, and customer base in key growth geographies including the Americas, Europe, and China in order to expand its market reach for reagents. Cisbio Bioassays is a custom assay service provider based in Codolet, France and was founded in 1974. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, and Merck. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cell based assays market is segmented - 1) By Product & Service: Consumables, Instruments, Services, Software  2) By Application: Drug Discovery, Basic Research, ADME Studies, Predictive Toxicology, Others 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Others 5) By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems

The stem cell market consist of sales of stem cells products such as human embryonic stem cell, induced pluripotent stem cell and adult stem cell. Stem cells are the autologous or allogenic cells that can grow into many types of cells in in-vivo and in-vitro environment. Stem cells therapy is designed to aid physician in performing medical treatment of neurodegenerative diseases, diabetes and heart disease. The stem cell market covered in this report is segmented by source into autologous, allogeneic. The stem cell therapy market is also segmented by product type into adult stem cell, human embryonic stem cell, induced pluripotent stem cell, others and by application into regenerative medicine, drug discovery and development. The global stem cell market is expected to grow from $20.59 billion in 2020 to $22.87 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The stem cell market is expected to reach $36 billion in 2025 at a CAGR of 12%. There is an increase in the prevalence of chronic diseases worldwide which drives the stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, by 2020, prevalence of chronic disease is predicted to increase by 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year. The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues. For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue at a clinic in Florida. These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the market. Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSC's are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis® for disease modeling and drug discovery. The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products. Celgene Corporation acquired Juno Therapeutics in March 2018, for $9 Billion. With this acquisition, Celgene will be positioned to become a leader in cellular immunotherapy. It is expected that with the addition of Juno’s JCAR017 therapy to their portfolio and other cellular immunotherapy products in Juno’s pipeline, Celgene would accelerate its revenue diversification. Juno Therapeutics, founded in 2013, is a Seattle-based biotech company which is into cutting-edge cancer immunotherapy treatments. Major players in the stem cell market are Anterogen Co. Ltd, Mesoblast Ltd, Osiris Therapeutics Inc, AlloSource, and Cellular Engineering Technologies. The regions covered in the stem cell market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global stem cell market is segmented - 1) By Source: Autologous, Allogeneic 2) By Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, Others 3) By Application: Regenerative Medicine, Drug Discovery And Development

The 3D cell culture technologies market consist of sales of 3D cell culture technologies and related services. Some of the 3D cell culture technologies include microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. The 3D cell culture technologies market does not include sales of cell culture consumables and instruments. This market is segmented into scaffold based, scaffold-free technologies and 3D bioreactors. The 3D cell culture technologies market covered in this report is segmented by type into scaffold-based, scaffold-free, 3D bioreactors. The 3D cell culture technologies market is also segmented by end users into research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, other end users; by scaffold-based into hydrogels, polymeric scaffolds, micropatterned surface microplates; by scaffold-free into hanging drop microplates, spheroid microplates, microfluidic 3D cell culture, magnetic levitations & 3d bioprinting and by application into cancer research, stem cell research, drug discovery, regenerative medicine. The global 3D cell culture technologies market is expected to grow from $1.63 billion in 2020 to $1.88 billion in 2021 at a compound annual growth rate (CAGR) of 15.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D cell culture technologies market is expected to reach $4.23 billion in 2025 at a CAGR of 22.5%. The increasing requirement for organ transplantation is driving the 3D cell culture technologies market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. According to the U.S. government information on organ donation and transplantation, 39,718 transplants were performed in 2019 and above 109,000 people are waiting for the transplant as of September 2020. The possibility of contaminating the cells is restricting the 3D cell culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D cell culture market. For example, various companies have adopted one such advancement into the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include the consistent documentation of the receipts. In 2018, Greiner Bio-One North America Inc. acquired 3D cell culture technology platform of Nano 3D Biosciences Inc. for an undisclosed amount. This will not only help Greiner Bio-One expand its portfolio but it will also help it strengthen its reach in the market. 3D cell culture is a disruptive technology in this market, it will help by improving the quality of results and pave new pathways towards disease treatment and prevention. Nano 3D Biosciences was established in 2008 and is headquartered in Texas, USA. Major players in the 3D cell culture technologies market are Nano3D Biosciences Corning Inc., Merck & Co., 3D Biotek LLC, 3D Biomatrix and Thermo Fisher Scientific. The regions covered in the 3D cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global 3D cell culture technologies market is segmented - 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-Based: Hydrogels, Polymeric Scaffolds, Micropatterned Surface Microplates 4) By Scaffold-Free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that utilizes the cells of the immune system to eliminate diseases including non-Hodgkin lymphoma, cancer, and acute lymphoblastic leukaemia. The global cellular immunotherapy market is expected to grow from $2.74 billion in 2020 to $3.59 billion in 2021 at a compound annual growth rate (CAGR) of 31%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.73 billion in 2025 at a CAGR of 17%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder the cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient cells as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast, and quality control production. For instance, in November 2019, Precision Biosciences, Inc., a biotechnology company, has created a new generation allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating its first off-the-shelf allogeneic CAR-T therapy candidate known as PBCAR0191. This is in collaboration with Servier, an international pharmaceutical company, and is mainly for the patients in need of advanced cancer treatment options. Additionally, in August 2020, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial for evaluating ACE1702 an allogeneic, off-the-shelf NK cell therapy for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialized in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies in advancing allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialized in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. The major players covered in the global cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Roche, Adicet Bio, ResTORbio, Celyad. The countries covered in the global cellular immunotherapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global cellular immunotherapy market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global cellular immunotherapy market is segmented - 1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin Lymphoma, Others 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Others

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that utilizes the cells of the immune system to eliminate diseases including non-Hodgkin lymphoma, cancer, and acute lymphoblastic leukaemia. The global cellular immunotherapy market is expected to grow from $2.74 billion in 2020 to $3.59 billion in 2021 at a compound annual growth rate (CAGR) of 31%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.73 billion in 2025 at a CAGR of 17%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder the cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient cells as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast, and quality control production. For instance, in November 2019, Precision Biosciences, Inc., a biotechnology company, has created a new generation allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating its first off-the-shelf allogeneic CAR-T therapy candidate known as PBCAR0191. This is in collaboration with Servier, an international pharmaceutical company, and is mainly for the patients in need of advanced cancer treatment options. Additionally, in August 2020, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial for evaluating ACE1702 an allogeneic, off-the-shelf NK cell therapy for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialized in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies in advancing allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialized in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. The major players covered in the global cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Roche, Adicet Bio, ResTORbio, Celyad. The countries covered in the global cellular immunotherapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global cellular immunotherapy market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global cellular immunotherapy market is segmented - 1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin Lymphoma, Others 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Others

The cell therapy market consists of sales of cell therapy and related services. Cell therapy (CT) helps repair or replace damaged tissues and cells. A variety of cells are used for the treatment of diseases includes skeletal muscle stem cells, hematopoietic (blood-forming) stem cells (HSC), lymphocytes, mesenchymal stem cells, pancreatic islet cells, and dendritic cells. The global cell therapy market is expected to grow from $7.2 billion in 2020 to $7.82 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.06 billion in 2025 at a CAGR of 11%. The rising prevalence of chronic diseases contributed to the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more and requires medical attention or limits daily activities or both and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit the patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. According to Cancer Research UK, in 2018, 17 million cancer cases were added to the existing list, and according to the International Diabetes Federation, in 2019, 463 million were living with diabetes. According to the Parkinson’s Foundation, every year, 60,000 Americans are diagnosed with PD, and more than 10 million people are living with PD worldwide. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market. The high cost of cell therapy hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people are looking for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost about $1,000 and, based on the condition, more specialized procedures can cost up to $ 100,000. In 2020, the average cost of stem cell therapy can range from $4000 - $8,000 in the USA. Therefore, the high cost of cell therapy restraints the growth of the cell therapy market. Key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. For instance, in April 2018, Eli Lilly, an American pharmaceutical company entered into a collaboration agreement with Sigilon Therapeutics, a biopharmaceutical company that focused on the discovery and development of living therapeutics to develop cell therapies for type 1 diabetes treatment by using the Afibromer technology platform. Similarly, in September 2018, CRISPR Therapeutics, a biotechnological company that develops transformative medicine using a gene-editing platform for serious diseases, and ViaCyte, a California-based regenerative medicine company, collaborated on the discovery, development, and commercialization of allogeneic stem cell therapy for diabetes treatment. In August 2019, Bayer AG, a Germany-based pharmaceutical and life sciences company, acquired BlueRock Therapeutics, an engineered cell therapy company, for $1 billion. Through this transaction, Bayer AG will acquire complete BlueRock Therapeutics’ CELL+GENE platform, including a broad intellectual property portfolio and associated technology platform including proprietary iPSC technology, gene engineering, and cell differentiation capabilities. BlueRock Therapeutics is a US-based biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. The major players covered in the global cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc., AlloCure, Arteriocyte Medical Systems, Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics, Forticell Bioscience, Mesoblast Ltd, AlloSource, Holostem Terapie Avanzate S.r.l, Pharmicell Co. Ltd, TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt. Ltd., Nipro Corp, Tego Science, Corestem Inc., Forticell Bioscience, Cellerant Therapeutics, Cells for Cells. The countries covered in the global cell therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global cell therapy market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global cell therapy market is segmented - 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Others